Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Inclusion Criteria: * Male or female, 18 years of age or older with documented HIV diagnosis. * Must be willing to comply with study-mandated evaluations; including discontinuation of current antiretroviral therapy during the treatment interruption. * Initiated HAART therapy within (≤) 1 year of HIV diagnosis or suspected infection. * Undetectable HIV-1 RNA for at least 2 months prior to screening and at screening. * CD4+ T-cell count ≥500 cells/µL. * Absolute neutrophil count (ANC) ≥ 2500/mm3. * Platelet count ≥ 200,000/mm3. Exclusion Criteria: * Acute or chronic hepatitis B or hepatitis C infection. * Active or recent (in prior 6 months) AIDS defining complication. * Any cancer or malignancy within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin or low grade (0 or 1) anal or cervical dysplasia. * Current diagnosis of NYHA grade 3 or 4 CHF, uncontrolled angina or uncontrolled arrhythmias. * History or any features on physical examination indicative of a bleeding diathesis. * Received HIV experimental vaccine within 6 months prior to screening, or any previous gene therapy using an integrating vector. * Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents within 30 days prior to screening. * Use of Aspirin, dipyridamole, warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2 week period prior to leukapheresis. * Currently participating in another clinical trial or participation in such a trial within 30 days prior to screening visit. * Currently taking maraviroc or have received maraviroc within 6 months prior to screening.